TG Therapeutics, Inc.

Total Valuation

TG Therapeutics, Inc. carries a market capitalization of 8.26B, placing it among publicly traded companies globally. Its enterprise value stands at 5.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

TG Therapeutics, Inc. currently has 153.09M shares outstanding.

Valuation Ratios

TG Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 10.42. The price-to-sales ratio is 6.87, and the price-to-book ratio stands at -4.53.

Enterprise Valuation

On an enterprise value basis, TG Therapeutics, Inc. trades at an EV/EBITDA multiple of 33.74 and an EV/FCF ratio of 55.72. The EV/Sales ratio of 7.21 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 33.80 provides insight into valuation relative to core operating earnings.

Financial Position

TG Therapeutics, Inc. maintains a current ratio of 5.81, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 129.23, indicating elevated leverage, while an interest coverage ratio of 5.42 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, TG Therapeutics, Inc. has paid -339.61M in income taxes, reflecting an effective tax rate of 60.63.

Stock Price Statistics

TG Therapeutics, Inc.'s stock has gained approximately 44.17424% over the past 52 weeks. The 50-day moving average sits at 47.64, while the 200-day moving average is 35.85.

Income Statement

Over the trailing twelve months, TG Therapeutics, Inc. generated 700.35M in revenue and converted that into 461.90M in net income, yielding earnings per share of 2.87. EBITDA reached 149.77M, while operating income came in at 149.50M.

Balance Sheet

TG Therapeutics, Inc. holds 514.43M in cash and equivalents against 753.56M in total debt, resulting in a net debt position of 302.93M. Total book value stands at -1.06B, with working capital of 899.86M providing operational flexibility.

Cash Flow

TG Therapeutics, Inc. produced -13.95M in operating cash flow over the past twelve months. After subtracting -240,000.00 in capital expenditures, free cash flow totaled -14.19M - equivalent to -0.10 per share.

Margins

TG Therapeutics, Inc. operates with a gross margin of 83.05, reflecting its pricing power and cost economics. The operating margin of 21.35 and net profit margin of 65.95 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

TG Therapeutics, Inc.'s most recent stock split took place on April 30, 2012 with a 225:4 split ratio.

Scores

TG Therapeutics, Inc. posts an Altman Z-Score of 3.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.